deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT02915432

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma

Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Conditions Esophageal Squamous Cell Carcinoma Gastric Adenocarcinoma Head and Neck Squamous Cell Carcinoma Nasopharyngeal Carcinoma
Interventions 240mg anti-PD-1 mAb JS001 Q3W 3 mg/kg anti-PD-1 mAb JS001 Q2W 360 mg anti-PD-1 mAb JS001 Q3W
Updated 17 times since 2017 Last updated: Dec 9, 2021 Started: Dec 31, 2016 Primary completion: Feb 19, 2020 Completion: Apr 30, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02915432, this PHASE1/PHASE2 trial focuses on Esophageal Squamous Cell Carcinoma and Gastric Adenocarcinoma and remains ongoing. Sponsored by Shanghai Junshi Bioscience Co., Ltd., it has been updated 17 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Mar 2017 · 59 days · monthly snapshot~Mar 2017 – ~May 2017 · 2 months · monthly snapshot~May 2017 – ~Feb 2018 · 9 months · monthly snapshot~Feb 2018 – ~Apr 2018 · 59 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~Nov 2019 · 7 months · monthly snapshot~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~Dec 2023 · 23 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2025 · 15 months · monthly snapshot~Dec 2025 – present · 8 months · monthly snapshot

Change History

17 versions recorded

  1. Dec 2025 — Present [monthly]

    Unknown PHASE1/PHASE2

  2. Sep 2024 — Dec 2025 [monthly]

    Unknown PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1/PHASE2

    Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Dec 2023 — Jul 2024 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Active Not Recruiting → Unknown Status

  5. Jan 2022 — Dec 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 12 earlier versions

  1. Jan 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Nov 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Apr 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Feb 2019 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  5. Dec 2018 — Feb 2019 [monthly]

    Recruiting PHASE1_PHASE2

  6. Oct 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  8. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Feb 2018 — Apr 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. May 2017 — Feb 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. Mar 2017 — May 2017 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Jan 2017 — Mar 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shanghai Junshi Bioscience Co., Ltd.
Data source: Shanghai Junshi Bioscience Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Changsha, China , Changzhou, China , Chengdu, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Harbin, China , Linyi, China and 9 more locations